Targeted agents and immunotherapies: optimizing outcomes in melanoma
Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …
Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes
SI Kim, CR Cassella, KT Byrne - Frontiers in immunology, 2021 - frontiersin.org
Cancer immunotherapy has revolutionized the treatment landscape in medical oncology, but
its efficacy has been variable across patients. Biomarkers to predict such differential …
its efficacy has been variable across patients. Biomarkers to predict such differential …
Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition
Transcriptomic signatures designed to predict melanoma patient responses to PD-1
blockade have been reported but rarely validated. We now show that intra-patient …
blockade have been reported but rarely validated. We now show that intra-patient …
Learning from clinical trials of neoadjuvant checkpoint blockade
Neoadjuvant checkpoint inhibition, in which the therapy is administered before surgery, is a
promising new approach to managing bulky but resectable melanoma, and is also being …
promising new approach to managing bulky but resectable melanoma, and is also being …
Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy
Background Patients with metastatic melanoma have variable responses to combination
ipilimumab and nivolumab. The objectives of this study were to examine the patterns of …
ipilimumab and nivolumab. The objectives of this study were to examine the patterns of …
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma–results of a prospective biomarker study
A Forschner, F Battke, D Hadaschik, M Schulze… - … for Immunotherapy of …, 2019 - Springer
Background Metastasized or unresectable melanoma has been the first malignant tumor to
be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the …
be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the …
Interactions in the (pre) metastatic niche support metastasis formation
G Doglioni, S Parik, SM Fendt - Frontiers in oncology, 2019 - frontiersin.org
Metastasis formation is the leading cause of death in cancer patients. Thus, understanding
and targeting this process is an unmet need. Crucial steps during the establishment of …
and targeting this process is an unmet need. Crucial steps during the establishment of …
Targeting tumor metabolism: a new challenge to improve immunotherapy
S Kouidhi, F Ben Ayed… - Frontiers in …, 2018 - frontiersin.org
Currently, a marked number of clinical trials on cancer treatment have revealed the success
of immunomodulatory therapies based on immune checkpoint inhibitors that activate tumor …
of immunomodulatory therapies based on immune checkpoint inhibitors that activate tumor …
Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma
L Khoja, C Maurice, MA Chappell, L MacMillan… - Cancer immunology …, 2016 - AACR
Anti–PD-1 inhibitors have significant activity in metastatic melanoma. Responses often occur
early and may be sustained. The optimal duration of treatment with these agents is …
early and may be sustained. The optimal duration of treatment with these agents is …
Therapy-induced modulation of the tumor microenvironment: new opportunities for cancer therapies
S Benavente, A Sánchez-García, S Naches… - Frontiers in …, 2020 - frontiersin.org
Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low
curability, but their effects are limited, and increasing evidence has implicated tumoral and …
curability, but their effects are limited, and increasing evidence has implicated tumoral and …